BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19725081)

  • 1. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
    ; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
    ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
    Carvalho JF; Louvel J; Doornbos ML; Klaasse E; Yu Z; Brussee J; IJzerman AP
    J Med Chem; 2013 Apr; 56(7):2828-40. PubMed ID: 23473309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
    Varkevisser R; Houtman MJ; Linder T; de Git KC; Beekman HD; Tidwell RR; Ijzerman AP; Stary-Weinzinger A; Vos MA; van der Heyden MA
    Br J Pharmacol; 2013 Jul; 169(6):1322-34. PubMed ID: 23586323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
    Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
    J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
    Yu Z; Klaasse E; Heitman LH; Ijzerman AP
    Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of negative allosteric modulators of the Kv11.1(hERG) channel.
    Yu Z; van Veldhoven JP; 't Hart IM; Kopf AH; Heitman LH; IJzerman AP
    Eur J Med Chem; 2015 Dec; 106():50-9. PubMed ID: 26519929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
    Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
    J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
    Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
    Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
    J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
    Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding of molecular substructures that contribute to hERG K+ channel blockade: synthesis and biological evaluation of E-4031 analogues.
    Vilums M; Overman J; Klaasse E; Scheel O; Brussee J; IJzerman AP
    ChemMedChem; 2012 Jan; 7(1):107-13. PubMed ID: 21919210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
    Snyders DJ; Chaudhary A
    Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the pH in state-dependent blockade of hERG currents.
    Wang Y; Guo J; Perissinotti LL; Lees-Miller J; Teng G; Durdagi S; Duff HJ; Noskov SY
    Sci Rep; 2016 Oct; 6():32536. PubMed ID: 27731415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel hypothesis for the binding mode of HERG channel blockers.
    Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
    Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
    Louvel J; Carvalho JF; Yu Z; Soethoudt M; Lenselink EB; Klaasse E; Brussee J; Ijzerman AP
    J Med Chem; 2013 Dec; 56(23):9427-40. PubMed ID: 24224763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
    Narayana Moorthy NS; Ramos MJ; Fernandes PA
    Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
    Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
    Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.